S&P REITERATES BUY OPINION ON IMMUNEX - 500 Beiträge pro Seite

[southbound]

S&P REITERATES BUY OPINION ON IMMUNEX
(IMNX 15.5*****)... 7/18/01 6:35 pm...
Q2 Enbrel sales of $183 mln. were $3 mln. below S&P expectation, total rev. of $238 mln. was $6 mln. above... EPS of $0.09 beat out est. of $0.06...Positive developments over next 12 months include completion of new Enbrel manufacturing plant, potential approval in psoriati carthritis, Phase III in psoriasis, and Phase II of ABX EGF in cancer.. We see EPS of $0.31 in `01, $0.37 in `02, $0.55 in `03... On net present value of products/pipeline and net cash, consider IMNX most undervalued of biotechs wecover...our 12 month price target is $30. /F.DiLorenzo

[southbound]

long@15.50$ am 19.07., aktuell 15.80$. Toll!

[southbound]

Letzte Woche sold@16.50$, weil das Teil nicht aus der Hüfte kam!

Gestern abend nachbörslich nicht gekauft wegen meiner
Erfahrung vom Juli!


Immunex Says Sales of Enbrel May Exceed $1 Billion Next Year
By Angela Zimm


Seattle, Aug. 20 (Bloomberg) -- Immunex Corp. said sales of its popular rheumatoid arthritis treatment Enbrel could reach as much as $1.3 billion next year as the company`s new Rhode Island facility begins operating in the second half of 2002.

Immunex said it expects Enbrel sales, which have been limited by manufacturing constraints, to range from $900 million to $1.3 billion next year. Company executives, who made the forecast at Immunex`s annual investors meeting today in Seattle, projected $4 billion in Enbrel sales by 2005.

Immunex said $900 million in Enbrel sales would be achieved through improved production yields and by exercising an option to buy unused manufacturing capacity from another biotechnology company. The balance of the $1.3 billion would come from production at Immunex`s Rhode Island plant.

``We now have something we can benchmark them against,`` said US Bancorp Piper Jaffray analyst Mark Augustine, who does not own Immunex shares.

Still, Augustine said he didn`t expect Enbrel sales to exceed $900 million next year because of the company`s timing on starting Enbrel production at the Rhode Island plant. Since announcing supply constraints last year, Immunex has pushed up the facility`s completion date to the second half of 2002 from early 2002, Augustine said.

``I think the $900 million is going to happen, with a potential upside from there,`` said investor Steven Payne, who owns Immunex shares.

Immunex reiterated its forecast of $750 million in Enbrel revenue this year. Sales of the drug, introduced in 1998, have grown faster than the company expected, forcing Immunex to limit its distribution.

Sales are also expected to benefit next year from Enbrel`s approval for psoriatic arthritis, the company said. Psoriatic arthritis, which affects about 300,000 Americans, is a complication of the chronic skin disorder psoriasis.

Immunex filed for U.S. Food and Drug Administration approval of Enbrel for psoriatic arthritis in July.

Also today, the company released preliminary study results that showed Enbrel appears to be effective in clearing skin lesions in patients with severe to moderate psoriasis.

Immunex said it plans to expand capacity through improvements in manufacturing processes that will increase production yields by 10 percent to 30 percent. The company may also increase Enbrel supply through an agreement to buy excess capacity from MedImmune Inc.

Under that agreement, Immunex would have the right of first refusal to buy unused capacity from MedImmune at German drugmaker Boehringer Ingelheim. Both Enbrel and MedImmune`s Synagis treatment for infant respiratory infection are manufactured by Boehringer Ingelheim at its plant

[southbound]

Schlußkurs an der oberen Begrenzung das mittelfristigen Abwärtstrends. Und dann das:


Immunex Corp. Reiterated `Hold` at Prudential
By Sybil Carlson

Princeton, New Jersey, Aug. 21 (Bloomberg Data) -- Immunex Corp. (IMNX US) was reiterated ``hold`` by analyst John S Sonnier at Prudential Securities. The price target is $14.

[southbound]

Im Intraday low exakt von 25er ema abgeprallt. Auch hier dürfte sich charttechnisch etwas entscheiden. Vor nachhaltigen Durchstoßen des Widerstandes bei 18$ sehe ich für mich kein Handlungsbedarf.
Vorbörslich schon wieder bei 17.10$.